Lasa Supergenerics, which had closed yesterday at Rs.81.75, opened today at Rs.86 and went on to hit a new high at Rs.88.65. Volumes have jumped up over 4 times.

The company had good news – it received an injunction order from the Bombay High Court, restraining its competitor from manufacturing albendazole in addition to other reliefs which is subject matter of patent infringement case, until disposal of suit.

The receipt of this relief is the milestones for Lasa, as it will restrain its competitor to manufacture and deal in one of the key product and enables the company to continue its leadership for its key products worldwide.

Lasa has subsisting process patent in its name for the invention titled “AN IMPROVED PROCESS FOR THE PREPARATION OF METHYL 5- (PROPYLTHIO)-1H-BENZO [D] IMIDAZOL-2-YLCARBAMATE" and it’s products based on the patented process and by use of its confidential information comprised over 85% of the company’s FY2020 revenues.

The company is a into manufacturing of Veterinary APIs, with manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. More than 25% of its APIs are exported to countries such as Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, and Pakistan.